Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

• Alzheimer's disease (AD) is the most common form of dementia.
• Effective therapies are not available yet.
• De-regulation of epigenetic processes play a role in AD.
• Targeting histone-modifying enzymes could be used to treat AD pathogenesis.

Alzheimer’ s disease (AD) is the most common form of dementia causing an increasing emotional and economical burden to our societies. Although much progress has been made regarding the molecular mechanisms that underlie AD pathogenesis effective therapies are not available yet. The emerging field of neuroepigenetics has provided evidence that de-regulation of epigenetic processes play a role in AD. In this article we will critically review the primary research data that led to the hypothesis that targeting histone-modifying enzymes could be used to treat AD pathogenesis and address the question if the field is ready to translate such findings into clinical application.This article is part of the Special Issue entitled ‘Neuroepigenetic Disorders’.